Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Nectar LifesciencesNSE:NECLIFE -1.04%51 Buyback Yield % is 40.48 as of Aug. 06, 2026, which is 10% below its 10-year median of 44.79. GuruFocus rates NSE:NECLIFE with a GF Score™ of 51/100 and a GF Value™ of ₹6.86 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 276 Drug Manufacturers companies, Nectar Lifesciences ranks better than 99.28% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Nectar Lifesciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Nectar Lifesciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Nectar Lifesciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nectar Lifesciences Buyback Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Nectar Lifesciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Nectar Lifesciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nectar Lifesciences (NSE:NECLIFE) has a Buyback Yield % of 40.48 as of Aug. 06, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nectar Lifesciences and its competitors. This is 10% below median its historical median of 44.79. Over the past decade, Nectar Lifesciences' Buyback Yield % has ranged from 40.48 to 44.79. According to the industry distribution chart, Nectar Lifesciences ranks #2 out of 276 companies in the Drug Manufacturers industry, placing it in the top 0.7%.
Is Nectar Lifesciences' Buyback Yield % too high?
Nectar Lifesciences' current Buyback Yield % of 40.48 is 10% below median its 10-year median of 44.79. Over the past 10 years, this metric has ranged from a low of 40.48 to a high of 44.79. Based on the distribution chart, Nectar Lifesciences ranks #2 out of 276 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Nectar Lifesciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Nectar Lifesciences' Buyback Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Nectar Lifesciences ranks #2 out of 276 companies for Buyback Yield %. This places Nectar Lifesciences in the top 1% of its industry — outperforming the majority of peers. Historically, Nectar Lifesciences' own Buyback Yield % has ranged from 40.48 to 44.79 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Drug Manufacturers company?
A good Buyback Yield % depends on the Drug Manufacturers industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Nectar Lifesciences and its competitors. Nectar Lifesciences's current Buyback Yield % is 40.48, which is 10% below median its own 10-year median of 44.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nectar Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Nectar Lifesciences (NSE:NECLIFE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹6.86, compared to a current price of ₹10.50 — trading 53.1% above its estimated fair value. The current Buyback Yield % is 40.48, which is 10% below median its 10-year median of 44.79. Nectar Lifesciences' overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Nectar Lifesciences (NSE:NECLIFE), the current Buyback Yield % is 40.48 as of Aug. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Nectar Lifesciences (NSE:NECLIFE) Overvalued in 2026?
Based on GuruFocus' analysis, Nectar Lifesciences stock appears to be overvalued.
The current stock price of ₹10.50 is trading 53.1% above its estimated GF Value™ of ₹6.86.
GuruFocus considers Nectar Lifesciences to be Significantly Overvalued.
Key valuation signals for NSE:NECLIFE:
Buyback Yield %: 40.48 (10% below median its 10-year median of 44.79)
GF Value™: ₹6.86 vs. price of ₹10.50 (53.1% above fair value)
No single metric tells the full story. See the NSE:NECLIFE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Nectar Lifesciences Ltd is an India-based pharmaceutical company specializing in Cephalosporins. It is engaged in manufacturing specialized pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and finished dosage formulations. It operates in the business segment of Pharmaceuticals Products. The Company is also in the Menthol business and succeeded in both domestic and international markets. Its business areas are APIs, Formulations, and Empty Hard Gelatin Capsules. Geographically, it derives a majority of its revenue from India.
51GF Score
Get the complete analysis for NSE:NECLIFE
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:NECLIFE has been successfully added to your 
